Safety and efficacy of AGN 203818 for pain associated with fibromyalgia syndrome

Trial Profile

Safety and efficacy of AGN 203818 for pain associated with fibromyalgia syndrome

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2012

At a glance

  • Drugs Rezatomidine (Primary)
  • Indications Fibromyalgia
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Jan 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 May 2011 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified February 2009).
    • 23 Feb 2009 Planned end date changed from Jan 2010 to Apr 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top